On March 4, 2022, Jerald Korn, the General Counsel and Chief Operating Officer of Kaleido Biosciences, Inc. (the Company), submitted notice to the Company of his resignation, effective March 18, 2022, to pursue another opportunity. The Company will be entering into a consulting agreement with Mr. Korn pursuant to which Mr. Korn will provide general administrative and other corporate services to the Company through April 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.26K | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- KLDO Stock
- News Kaleido Biosciences, Inc.
- Kaleido Biosciences, Inc. Announces Resignation of Jerald Korn, the General Counsel and Chief Operating Officer, Effective March 18, 2022